Targeting CV risk factors with GLP-1 RAs in people with obesity

Professor Michael Lincoff shares with us a discussion occurred during the EASD 2022 meeting, this was focusing on the modification of cardiovascular risk in patients with obesity with the GLP-1 receptor agonists.

Once weekly insulin: The ONWARDS 2 study

Professor Tina Vilsbøll chaired a very interesting session looking into once weekly insulin.

Is HFpEF hiding in your practice? Key messages of the DELIVER study: Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

We asked Professor Silvio Inzucchi about the key messages of the DELIVER study, he talked about this topic at the recent EASD 2022.

Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity

Professor Timothy Garvey, Director of Diabetes Research Center at University of Alabama presented new data from the STEP trial program at this year EASD Congress in Stockholm.

Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycaemia in adults with overweight or obesity vs liraglutide 3.0 mg

Domenica Rubino, Director of Washington Center for Weight Management & Research at Arlington, Virginia, USA, held a very interesting lecture about weight control at the recent EASD 2022 Congress.

Let’s talk about CGM evidence: Using basal insulins in T1D in daily life and when exercising

Continuous glucose monitoring gives us the opportunity to better analyze diabetes. The new insights help us to improve the therapy of our patients in the active daily life and even during physical exercise. Dr. Othmar Moser held two lectures about this topic the recent EASD 2022 congress.

Effect of liraglutide on muscle fat infiltration in adults with overweight or obesity

Professor Ambarish Pandey presented the results a randomised clinical trial about the effect of liraglutide on muscle fat infiltration in overweight or obesity adults at the recent EASD 2022 Congress. We asked him about the result.